目的 探讨卡左双多巴控释片联合多巴丝肼片治疗帕金森病的临床疗效。方法 选取2014年1月—2016年1月眉山市人民医院收治的帕金森患者123例为研究对象，所有患者随机分为对照组（59例）和治疗组（64例）。对照组口服多巴丝肼片，初始剂量为0.125 g/次，3次/d，服用1周后，根据个人病情逐渐增加治疗量至最大剂量，并维持最大剂量不超过1.5 g/d（至少分3次服用）。治疗组在对照组基础上口服卡左双多巴缓释片，125 mg/次，1次/12 h。两组患者均连续治疗12个月。观察两组的临床疗效，比较两组的帕金森病综合评分量表（UPDRS）评分、简易智力状态检查量表（MMSE）评分和蒙特利尔认知评估量表（MoCA）评分。结果 治疗后，对照组和治疗组的总有效率分别为71.19%、84.38%，两组比较差异有统计学意义（P<0.05）。治疗后，两组UPDRS各级评分均显著下降，同组治疗前后比较差异有统计学意义（P<0.05）；且治疗组UPDRS评分明显低于对照组，两组比较差异具有统计学意义（P<0.05）。治疗后，两组MMSE评分、MoCA评分均显著升高，同组治疗前后比较差异有统计学意义（P<0.05）；且治疗组这些观察指标明显高于对照组，两组比较差异具有统计学意义（P<0.05）。结论 卡左双多巴控释片联合多巴丝肼片治疗帕金森病具有较好的临床疗效，可改善患者认知功能，安全性较好，具有一定临床推广应用价值。

Objective To investigate the clinical effect of Carbidopa and Levodopa Sustained-release Tablets combined with Levodopa and Benserazide Hydrochloride Tablets in treatment of Parkinson's disease. Methods Patients (123 cases) with Parkinson's disease in Meishan City People's Hospital from January 2014 to January 2016 were randomly divided into the control group (59 cases) and the treatment group (64 cases). Patients in the control group were po administered with Levodopa and Benserazide Hydrochloride Tablets, starting dosage 0.125 g/time, three times daily, after 1 week, gradually increased the amount of treatment to the maximum dose and maintained the maximum dose of not more than 1.5 g/d (at least 3 times) according to the individual's condition. Patients in the treatment group were po administered with Carbidopa and Levodopa Sustained-release Tablets on the basis of the control group, 125 mg/time, 1 time/12 h. Patients in two groups were treated for 12 months. After treatment, the clinical efficacies were evaluated, and UPDRS scores, MMSE scores, and MoCA scores in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 71.19% and 84.38%, respectively, and there was difference between two groups (P < 0.05). After treatment, the various grade of UPDRS score in two groups were significantly decreased, and the difference was statistically significant in the same group (P < 0.05). And the observational indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P < 0.05). After treatment, MMSE scores and MoCA scores in two groups were significantly increased, and the difference was statistically significant in the same group (P < 0.05). And the observational indexes in the treatment group were significantly higher than those in the control group, with significant difference between two groups (P < 0.05). Conclusion Carbidopa and Levodopa Sustained-release Tablets combined with Levodopa and Benserazide Hydrochloride Tablets has clinical curative effect in treatment of Parkinson's disease, can improve cognitive function, with good safety, which has a certain clinical application value.